Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors

► The ability of urea-derivatives (4a-e) to be recognized by p38 MAPK was determined by docking studies. ► Compound 4e showed a better score value compared to the prototype GK-00687. ► Anti-inflammatory and analgesic activities of compound 4e were demonstrated. ► Compound 4e is a weak inhibitor of TNF-alfa production and p38 MAPK.